IL-4/IL-13 Kinoid

About Neovacs

Founded in 1993, Neovacs is a Paris-based biotech that historically focused on its innovative Kinoid® active immunotherapy platform, designed to induce a patient's own immune system to regulate harmful cytokines. Following a judicial reorganization in 2020, the company pivoted to a hybrid model, pairing the management of its legacy pipeline with strategic investments in external biotech and medtech companies. This strategy aims to leverage internal expertise for portfolio growth while seeking to revive its core R&D programs under improved financial conditions.

Therapeutic Areas